Jump to content

TC-S 7001: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
No edit summary
Importing Wikidata short description: "Chemical compound" (Shortdesc helper)
 
(13 intermediate revisions by 6 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}
{{Drugbox
{{Drugbox
| IUPAC_name = 6-chloro-4-N-[3,5-difluoro-4-[(3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]pyrimidine-2,4-diamine
| IUPAC_name = 6-chloro-4-N-[3,5-difluoro-4-[(3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]pyrimidine-2,4-diamine
Line 6: Line 7:
| legal_US =
| legal_US =
| legal_status =
| legal_status =

<!--Pharmacokinetic data-->
<!--Pharmacokinetic data-->
| bioavailability =
| bioavailability =
Line 12: Line 12:
| elimination_half-life =
| elimination_half-life =
| excretion =
| excretion =

<!--Identifiers-->
<!--Identifiers-->
| CAS_number = 867017-68-3
| CAS_number = 867017-68-3
| PubChem = 11524200
| PubChem = 11524200
| ChemSpiderID =
| ChemSpiderID = 9698986
| ChEMBL = 1971943

<!--Chemical data-->
<!--Chemical data-->
| C=18 | H=13 | Cl=1 | F=2 | N=6 | O=1
| C=18 | H=13 | Cl=1 | F=2 | N=6 | O=1
Line 25: Line 24:
}}
}}


'''TCS-7001''' ('''Azaindole-1''') is a drug which acts as a potent and selective inhibitor of the [[enzyme]] [[Rho kinase]], with an IC<sub>50</sub> of 0.6 nM at [[ROCK1]] and 1.1 nM at [[ROCK2]].<ref>Kast R, Schirok H, Figueroa-Pérez S, Mittendorf J, Gnoth MJ, Apeler H, Lenz J, Franz JK, Knorr A, Hütter J, Lobell M, Zimmermann K, Münter K, Augstein KH, Ehmke H, Stasch JP. Cardiovascular effects of a novel potent and highly selective azaindole-based inhibitor of Rho-kinase. ''Br J Pharmacol''. 2007 Dec;152(7):1070-80. {{doi|10.1038/sj.bjp.0707484}} {{pmid|17934515}}</ref> It has [[vasodilator]]y effects and has been used in research for a variety of applications.<ref>Dahal BK, Kosanovic D, Pamarthi PK, Sydykov A, Lai YJ, Kast R, Schirok H, Stasch JP, Ghofrani HA, Weissmann N, Grimminger F, Seeger W, Schermuly RT. Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension. ''Eur Respir J''. 2010 Oct;36(4):808-18. {{doi|10.1183/09031936.00140309}} {{pmid|20530035}}</ref><ref>Pankey EA, Byun RJ, Smith WB 2nd, Bhartiya M, Bueno FR, Badejo AM, Stasch JP, Murthy SN, Nossaman BD, Kadowitz PJ. The Rho kinase inhibitor azaindole-1 has long-acting vasodilator activity in the pulmonary vascular bed of the intact chest rat. ''Can J Physiol Pharmacol''. 2012 Jul;90(7):825-35. {{doi|10.1139/y2012-061}} {{pmid|22591047}}</ref><ref>Lasker GF, Pankey EA, Allain AV, Murthy SN, Stasch JP, Kadowitz PJ. The selective Rho-kinase inhibitor azaindole-1 has long-lasting erectile activity in the rat. ''Urology''. 2013 Feb;81(2):465.e7-14. {{doi|10.1016/j.urology.2012.10.039}} {{pmid|23374844}}</ref>
'''TC-S 7001''' ('''Azaindole-1''') is a drug which acts as a potent and selective inhibitor of the [[enzyme]] [[Rho kinase]], with an IC<sub>50</sub> of 0.6 nM at [[ROCK1]] and 1.1 nM at [[ROCK2]].<ref>{{cite journal | vauthors = Kast R, Schirok H, Figueroa-Pérez S, Mittendorf J, Gnoth MJ, Apeler H, Lenz J, Franz JK, Knorr A, Hütter J, Lobell M, Zimmermann K, Münter K, Augstein KH, Ehmke H, Stasch JP | display-authors = 6 | title = Cardiovascular effects of a novel potent and highly selective azaindole-based inhibitor of Rho-kinase | journal = British Journal of Pharmacology | volume = 152 | issue = 7 | pages = 1070–80 | date = December 2007 | pmid = 17934515 | doi = 10.1038/sj.bjp.0707484 | pmc = 2095102 }}</ref> It has [[vasodilator]]y effects and has been used in research for a variety of applications.<ref>{{cite journal | vauthors = Dahal BK, Kosanovic D, Pamarthi PK, Sydykov A, Lai YJ, Kast R, Schirok H, Stasch JP, Ghofrani HA, Weissmann N, Grimminger F, Seeger W, Schermuly RT | display-authors = 6 | title = Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension | journal = The European Respiratory Journal | volume = 36 | issue = 4 | pages = 808–18 | date = October 2010 | pmid = 20530035 | doi = 10.1183/09031936.00140309 | s2cid = 10991200 | doi-access = free }}</ref><ref>{{cite journal | vauthors = Pankey EA, Byun RJ, Smith WB, Bhartiya M, Bueno FR, Badejo AM, Stasch JP, Murthy SN, Nossaman BD, Kadowitz PJ | display-authors = 6 | title = The Rho kinase inhibitor azaindole-1 has long-acting vasodilator activity in the pulmonary vascular bed of the intact chest rat | journal = Canadian Journal of Physiology and Pharmacology | volume = 90 | issue = 7 | pages = 825–35 | date = July 2012 | pmid = 22591047 | doi = 10.1139/y2012-061 }}</ref><ref>{{cite journal | vauthors = Lasker GF, Pankey EA, Allain AV, Murthy SN, Stasch JP, Kadowitz PJ | title = The selective Rho-kinase inhibitor azaindole-1 has long-lasting erectile activity in the rat | journal = Urology | volume = 81 | issue = 2 | pages = 465.e7–14 | date = February 2013 | pmid = 23374844 | doi = 10.1016/j.urology.2012.10.039 | pmc = 3564057 }}</ref>

== See also ==
* [[Rho kinase inhibitor]]


== References ==
== References ==
Line 32: Line 34:


{{pharm-stub}}
{{pharm-stub}}



[[Category:Enzyme inhibitors]]
[[Category:Enzyme inhibitors]]
[[Category:Pyrrolopyridines]]
[[Category:Pyrimidines]]
[[Category:Fluoroarenes]]
[[Category:Chloroarenes]]
[[Category:Aromatic ethers]]

Latest revision as of 10:26, 23 April 2022

TC-S 7001
Identifiers
  • 6-chloro-4-N-[3,5-difluoro-4-[(3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]pyrimidine-2,4-diamine
CAS Number
PubChem CID
ChemSpider
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H13ClF2N6O
Molar mass402.79 g·mol−1
3D model (JSmol)
  • CC1=CNC2=NC=CC(=C12)OC3=C(C=C(C=C3F)NC4=CC(=NC(=N4)N)Cl)F
  • InChI=1S/C18H13ClF2N6O/c1-8-7-24-17-15(8)12(2-3-23-17)28-16-10(20)4-9(5-11(16)21)25-14-6-13(19)26-18(22)27-14/h2-7H,1H3,(H,23,24)(H3,22,25,26,27)
  • Key:NRSGWEVTVGZDFC-UHFFFAOYSA-N

TC-S 7001 (Azaindole-1) is a drug which acts as a potent and selective inhibitor of the enzyme Rho kinase, with an IC50 of 0.6 nM at ROCK1 and 1.1 nM at ROCK2.[1] It has vasodilatory effects and has been used in research for a variety of applications.[2][3][4]

See also

[edit]

References

[edit]
  1. ^ Kast R, Schirok H, Figueroa-Pérez S, Mittendorf J, Gnoth MJ, Apeler H, et al. (December 2007). "Cardiovascular effects of a novel potent and highly selective azaindole-based inhibitor of Rho-kinase". British Journal of Pharmacology. 152 (7): 1070–80. doi:10.1038/sj.bjp.0707484. PMC 2095102. PMID 17934515.
  2. ^ Dahal BK, Kosanovic D, Pamarthi PK, Sydykov A, Lai YJ, Kast R, et al. (October 2010). "Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension". The European Respiratory Journal. 36 (4): 808–18. doi:10.1183/09031936.00140309. PMID 20530035. S2CID 10991200.
  3. ^ Pankey EA, Byun RJ, Smith WB, Bhartiya M, Bueno FR, Badejo AM, et al. (July 2012). "The Rho kinase inhibitor azaindole-1 has long-acting vasodilator activity in the pulmonary vascular bed of the intact chest rat". Canadian Journal of Physiology and Pharmacology. 90 (7): 825–35. doi:10.1139/y2012-061. PMID 22591047.
  4. ^ Lasker GF, Pankey EA, Allain AV, Murthy SN, Stasch JP, Kadowitz PJ (February 2013). "The selective Rho-kinase inhibitor azaindole-1 has long-lasting erectile activity in the rat". Urology. 81 (2): 465.e7–14. doi:10.1016/j.urology.2012.10.039. PMC 3564057. PMID 23374844.
Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=TC-S_7001&oldid=1084241629"